APG Asset Management N.V. Decreases Position in C.R. Bard, Inc. (BCR)

APG Asset Management N.V. reduced its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 41.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 492,552 shares of the medical instruments supplier’s stock after selling 351,914 shares during the period. APG Asset Management N.V. owned 0.68% of C.R. Bard worth $155,701,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in BCR. UBS Asset Management Americas Inc. increased its position in C.R. Bard by 3.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 267,451 shares of the medical instruments supplier’s stock valued at $60,087,000 after buying an additional 9,134 shares during the period. Perigon Wealth Management LLC increased its position in C.R. Bard by 14.6% in the fourth quarter. Perigon Wealth Management LLC now owns 2,566 shares of the medical instruments supplier’s stock valued at $631,000 after buying an additional 327 shares during the period. Teachers Advisors LLC increased its position in C.R. Bard by 3.5% in the fourth quarter. Teachers Advisors LLC now owns 134,481 shares of the medical instruments supplier’s stock valued at $30,213,000 after buying an additional 4,500 shares during the period. Kentucky Retirement Systems acquired a new position in C.R. Bard during the fourth quarter valued at approximately $1,199,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new position in C.R. Bard during the fourth quarter valued at approximately $535,000. 77.14% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard, Inc. (NYSE BCR) traded down 0.30% during midday trading on Friday, hitting $318.20. 431,723 shares of the stock traded hands. The company has a 50-day moving average of $319.58 and a 200-day moving average of $286.55. The stock has a market cap of $23.12 billion, a PE ratio of 41.77 and a beta of 0.59. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. During the same quarter last year, the business posted $2.54 earnings per share. C.R. Bard’s revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts anticipate that C.R. Bard, Inc. will post $11.82 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is 13.67%.

TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/19/c-r-bard-inc-bcr-stake-reduced-by-apg-asset-management-n-v-updated-updated-updated.html.

Several brokerages recently commented on BCR. Cowen and Company lifted their price target on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a report on Monday, April 24th. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price on the stock in a report on Tuesday, June 6th. Jefferies Group LLC boosted their target price on shares of C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a report on Monday, April 24th. Finally, Wells Fargo & Company cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the sale, the insider now owns 31,445 shares in the company, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is owned by company insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit